The European Commission (EC), the European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA) have affirmed their commitment to regulatory cooperation and to intensifying their interactions in several new areas.
Medicines Regulators on Both Sides of the Atlantic Confirm Commitment to Cooperation on Medicines
The European Commission (EC), the European Medicines Agency (EMEA) and the United States Food and Drug Administration (FDA) have affirmed their commitment to regulatory cooperation and to intensifying their interactions in several new areas.
Meeting in London on 30 September and 1 October 2008 for the annual review of cooperative activities undertaken under the scope of their
confidentiality arrangements, the European Union and United States authorities agreed to expand cooperation in the areas of advanced-therapy medicines and nanotechnology-derived medicinal products, as well as on the exchange of pharmacovigilance information. This builds on achievements made previously in areas such as oncology, vaccines, orphan medicines and paediatric medicines.
Notable progress has been made on implementing the Transatlantic Administrative Simplification initiative since its launch in November
2007, particularly in the areas of inspections, qualification of biomarkers, paediatrics and advanced-therapy medicines.
The EU–US confidentiality arrangements on medicines for human use were first signed in September 2003 and extended for a further five years in
September 2005. Similar arrangements covering veterinary medicines, which allow the EC/EMEA and the FDA to exchange confidential information as part of their regulatory processes relating to the veterinary sector, were signed in May 2008.
Having been in place for five years, both sides concur that the transatlantic cooperation activities continue to be successful in protecting and promoting global human and animal health, reducing the regulatory burden and costs so that innovative medicines can be brought
to patients in a timely manner, while also allowing critical safety information about medicines to be shared between the US and EU regulatory authorities.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.